The U.S. Securities and Exchange Commission has asked Pfizer Inc. for information about two of its painkillers, Celebrex and Bextra, the Associated Press reported Tuesday.

The company wouldn’t elaborate, except to say it is cooperating with the request, which was made in the second quarter of this year, the wire service said. Both drugs belong to a class of painkillers called cox-2 inhibitors, which also includes the Merck and Co. drug Vioxx.

Bextra and Vioxx have been withdrawn from U.S. markets after research linked them to higher rates of heart attack and stroke in long-term users.

Merck withdrew Vioxx September 30, 2004 and Pfizer pulled Bextra from pharmacy shelves in April, 2005.

Celebrex remains on the market but includes new warnings required by the U.S. Food and Drug Administration about possible cardiovascular risks.



We're here to help!

We live by our creed of “helping those who need it most” and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked * may be required for submission.


Beasley Allen Law Firm
What is Celebrex? Celebrex is in a group of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs)....
Beasley Allen Law Firm
What is Bextra? Bextra is valdecoxib-based drug that is administered orally. Bextra is used as treatment...

Best firm by far

Our case was handled with the utmost integrity and professionalism. If I could give them 10 stars, I would. This is the best legal firm I have ever dealt with by far.

—Pat